Skip to content
Search

Latest Stories

Polio vaccine makers failing to make enough doses: WHO experts

Two companies making vaccines to help the world eradicate polio are failing to produce enough, so many countries should prepare to give lower doses to make stocks last, a group of experts has advised the World Health Organization.

With polio on the brink of eradication globally, the WHO wants to see a worldwide switch from the traditional “live” oral polio vaccine, which runs the risk of spreading the disease, to an inactivated vaccine that needs to be injected.


But WHO’s Strategic Advisory Group of Experts (SAGE), which meets twice a year, said a severe shortage of inactivated vaccine means many countries should use a fractional dose, via an intra-dermal rather than intra-muscular injection, allowing each dose to go twice as far.

“There are only two manufacturers of the vaccine and they are having some problems with production of the vaccine, and getting enough raw material of the polio virus,” SAGE Chairman Jon Abramson told reporters on a conference call on Friday (21).

Polio is a contagious viral disease which invades the nervous system and can cause irreversible paralysis within hours.

“Each time we hear that there’s a further reduction in the amount that can be anticipated, we have to make further adjustments,” Abramson said. “My hope is this problem can be solved by 2018. But I can’t promise that, obviously. It’s not something we can control.”

The two manufacturers are French drugmaker Sanofi Pasteur and Asia’s largest vaccine maker, Serum Institute of India Ltd, owned by the billionaire Cyrus Poonawalla.

A spokesman for Sanofi Pasteur said the company was on track to meet its commitments as part of its 2016-2017 delivery plan and should be able to supply more doses in 2018. No comment was available on Friday evening from Serum Institute of India.

WHO polio spokeswoman Sona Bari said that the production was about 40 percent below what had been requested, leaving about 50 countries without adequate supplies.

The economic savings of the polio program, between 1988 and whenever the disease is eradicated, were estimated at $50 billion (£41 billion), she said.

More For You

Shefali Jariwala

Glutathione and anti ageing drugs under spotlight after Shefali Jariwala death

Instagram/shefalijariwala

Did anti-ageing pills, beauty supplements and glutathione trigger Shefali Jariwala’s death?

Quick highlights:

  • Shefali Jariwala died at 42 in Mumbai after reportedly collapsing post-fast; cause of death suspected to be cardiac arrest or blood pressure drop.
  • Police found anti-ageing pills, vitamin supplements, and glutathione injections at her residence.
  • Doctors stress the risks of unsupervised use of hormone-based and anti-ageing treatments.
  • Final post-mortem report expected in two days; no foul play suspected, case treated as accidental death.

The untimely death of actor-model Shefali Jariwala has sparked renewed concern over the unregulated use of anti-ageing treatments and self-medication. The 42-year-old, best known for her appearance in Kaanta Laga, was declared dead on arrival at a Mumbai hospital on Friday night. Initial investigations suggest she may have suffered a cardiac arrest following a steep drop in blood pressure, possibly linked to taking supplements on an empty stomach.

Keep ReadingShow less
Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less